
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Shenzhen Edge Medical Co., Ltd., you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2675)

- (1) 2025 REPORT OF THE BOARD OF DIRECTORS**
 - (2) 2025 REPORT OF THE SUPERVISORY COMMITTEE**
 - (3) 2025 ANNUAL REPORT**
 - (4) 2025 PROFIT DISTRIBUTION PLAN**
 - (5) RE-APPOINTMENT OF AUDITOR**
 - (6) PROPOSED AUTHORIZATION TO THE BOARD TO FIX THE REMUNERATION OF DIRECTORS AND SUPERVISORS**
 - (7) PROPOSED CHANGE OF COMPANY TYPE**
 - (8) PROPOSED GENERAL MANDATE TO ISSUE SHARES**
 - (9) PROPOSED GENERAL MANDATE TO REPURCHASE H SHARES**
 - (10) PROPOSED CHANGE OF REGISTERED ADDRESS AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION**
- AND**
- NOTICE OF ANNUAL GENERAL MEETING**

Capitalized terms used in this cover page have the same meanings as those defined in the section headed "Definitions" in this circular.

The notice convening the Annual General Meeting of the Company to be held at Multi-function Hall, 19/F, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC on Thursday, June 25, 2026 at 10:00 a.m. is set out on pages 16 to 21 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.edgemed.cn).

Whether or not you are able to attend the Annual General Meeting, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible but in any event not less than 24 hours before the time appointed for the holding of the Annual General Meeting (i.e. not later than 10:00 a.m. on Wednesday, June 24, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the Annual General Meeting if you so wish.

References to time and dates in this circular are to Hong Kong time and dates.

June 3, 2026

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX I - EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE	10
APPENDIX II - PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION.	14
NOTICE OF ANNUAL GENERAL MEETING	16

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“Annual General Meeting” or “AGM”	the annual general meeting of the Company to be held at Multi-function Hall, 19/F, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC on Thursday, June 25, 2026 at 10:00 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 16 to 21 of this circular, or any adjournment thereof
“Articles of Association”	the articles of association of the Company, as amended from time to time
“Board” or “Board of Directors”	the board of Directors of the Company
“China” or “PRC”	the People’s Republic of China excluding, for the purpose of this circular, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Company”	Shenzhen Edge Medical Co., Ltd. (深圳市精鋒醫療科技股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (Stock code: 2675)
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries from time to time
“H Share(s)”	overseas listed share(s) in the share capital of the Company with a nominal value of RMB1.0 each, listed on the Main Board of the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Issue General Mandate”	a general mandate proposed to be granted to the Directors at the Annual General Meeting to allot, issue and/or deal with Shares (including the sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued Shares (excluding treasury shares, if any) as at the date of passing such resolution at the Annual General Meeting

DEFINITIONS

“Latest Practicable Date”	May 29, 2026, being the latest practicable date prior to the date of this circular for the purpose of ascertaining certain information contained in this circular
“Listing Date”	January 8, 2026, being the date on which the H Shares were listed on the Main Board of the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Repurchase Mandate”	a general mandate proposed to be granted to the Directors at the AGM to repurchase up to 10% of the total number of issued H Shares (excluding any treasury shares) as at the date of passing such resolution at the AGM
“RMB”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising Unlisted Share(s) and H Share(s)
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisor(s)”	the supervisor(s) of the Company
“Takeovers Code”	The Code on Takeovers and Mergers approved by the Securities and Futures Commission as amended from time to time
“Unlisted Shares”	ordinary share(s) in the capital of the Company with a nominal value of RMB1.0 each which are unlisted on any stock exchange
“%”	per cent

LETTER FROM THE BOARD



Shenzhen Edge Medical Co., Ltd. **深圳市精鋒醫療科技股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2675)

Executive Directors:

Dr. Wang Jianchen (*Chairman of the Board*)
Dr. Gao Yuanqian
Ms. Wu Mengyuan

Non-executive Directors:

Mr. Sheng Li
Mr. Chen Gang
Mr. Qiu Xiang

Independent Non-executive Directors:

Mr. Yang Fan
Mr. Zhang Guoguang
Mr. Lau Ying Kit

Registered Office:

Room 1901, Building 2B
Smart Park Phase II, Baolong Street
Longgang District
Shenzhen
PRC

*Head Office and Principal Place of
Business in the PRC:*

Room 1901, Building 2B
Smart Park Phase II, Baolong Street
Longgang District
Shenzhen
PRC

*Principal Place of Business
in Hong Kong:*

Room 1918, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong

June 3, 2026

To the Shareholders

Dear Sir/Madam,

- (1) 2025 REPORT OF THE BOARD OF DIRECTORS**
 - (2) 2025 REPORT OF THE SUPERVISORY COMMITTEE**
 - (3) 2025 ANNUAL REPORT**
 - (4) 2025 PROFIT DISTRIBUTION PLAN**
 - (5) RE-APPOINTMENT OF AUDITOR**
 - (6) PROPOSED AUTHORIZATION TO THE BOARD TO FIX THE
REMUNERATION OF DIRECTORS AND SUPERVISORS**
 - (7) PROPOSED CHANGE OF COMPANY TYPE**
 - (8) PROPOSED GENERAL MANDATE TO ISSUE SHARES**
 - (9) PROPOSED GENERAL MANDATE TO REPURCHASE H SHARES**
 - (10) PROPOSED CHANGE OF REGISTERED ADDRESS AND AMENDMENTS
TO THE ARTICLES OF ASSOCIATION**
- AND**
NOTICE OF ANNUAL GENERAL MEETING

I. INTRODUCTION

The purpose of this circular is to provide you with the notice of the Annual General Meeting and the information reasonably necessary to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the Annual General Meeting.

LETTER FROM THE BOARD

At the Annual General Meeting, resolutions will be proposed to consider and if thought fit, approve:

ORDINARY RESOLUTIONS

- (1) the report of the Board of Directors for the year 2025 (the “**2025 Report of the Directors**”);
- (2) the report of the supervisory committee of the Company for the year 2025 (the “**2025 Report of the Supervisory Committee**”);
- (3) the annual report of the Company for the year 2025 (the “**2025 Annual Report**”);
- (4) the profit distribution plan of the Company for the year 2025 (the “**2025 Profit Distribution Plan**”);
- (5) the re-appointment of auditor of the Company for the year 2026;
- (6) the proposed authorization to the Board to fix the remuneration of directors and supervisors; and
- (7) the proposed change of company type of the Company.

SPECIAL RESOLUTIONS

- (8) the proposed Issue General Mandate;
- (9) the proposed Repurchase Mandate; and
- (10) the proposed change of registered address and amendments to the Articles of Association.

II. DETAILS OF THE RESOLUTIONS

ORDINARY RESOLUTIONS

(1) **2025 Report of the Directors**

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 Report of the Directors, the full text of which is set out in the 2025 Annual Report.

(2) **2025 Report of the Supervisory Committee**

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 Report of the Supervisory Committee, the full text of which is set out in the 2025 Annual Report.

LETTER FROM THE BOARD

(3) 2025 Annual Report

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 Annual Report. The 2025 Annual Report is set out and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.edgemed.cn).

(4) 2025 Profit Distribution Plan

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 Profit Distribution Plan. Based on the financial condition and business development of the Company, as of now, the Company does not have any distributable profits. The Company has resolved not to carry out any profit distribution or convert any capital reserve into registered share capital for the year ended December 31, 2025.

(5) Re-appointment of Auditor for the Year 2026

An ordinary resolution will be proposed at the AGM for the Shareholders to consider and approve the re-appointment of KPMG to be the auditor of the Company for the year ending December 31, 2026 with a term commencing from the date of approval at the AGM until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix its remuneration for the year ending December 31, 2026.

The estimated fee for the annual audit and interim review services of the consolidated financial statements of the Group for the financial year ending December 31, 2026 is expected to be in the range of approximately RMB2,300,000 to RMB3,000,000.

The estimated fee represents a fair and reasonable estimation, after due consideration and arm's length negotiation between the Company and KPMG. The estimation takes into account various factors such as the size and structure of the Group, the nature and complexity of the Group's businesses, the expected scope, timetable and direction of the audit and the time and resources deployed by the auditor.

Furthermore, the estimated fee assumes there will be no material changes in the Group's businesses and operations, accounting policies or regulatory environment, and that the Company will provide timely and adequate assistance and information as required for the audit.

(6) Proposed Authorization to the Board to Fix the Remuneration of Directors and Supervisors

An ordinary resolution will be proposed at the Annual General Meeting to authorize the Board to fix the remuneration of Directors and Supervisors. The remuneration of the executive Directors of the Company includes salaries, allowances and other benefits, discretionary bonuses, retirement scheme contributions, and equity-settled share-based payments. The non-executive Directors of the Company will not receive any remuneration from the Company, while the independent non-executive Directors will receive Director's fees. The remuneration

LETTER FROM THE BOARD

of the Supervisors includes salaries, allowances and other benefits, discretionary bonuses, retirement scheme contributions, and equity-settled share-based payments. The remuneration of the Directors and Supervisors is determined based on the respective responsibilities, qualifications, positions, seniority, and individual performance of each Director and Supervisor, as well as the operating performance of the Group and comparable market practices.

(7) Proposed Change of Company Type

Given that the Company has been listed on the Main Board of the Stock Exchange, the company type of the Company shall be changed from a joint stock company (foreign-invested, unlisted) to a joint stock company (foreign-invested, listed). An ordinary resolution will be proposed at the Annual General Meeting to authorize the Board, and the Board to further authorize the management of the Company, to approve and/or execute on behalf of the Company all the acts, deeds, documents, registrations, filings and other matters which are necessary, appropriate, desirable or relevant to the proposed change of company type of the Company.

SPECIAL RESOLUTIONS

(8) Proposed General Mandate to Issue Shares

In order to ensure flexibility and to give discretion to the Board in the event that it becomes desirable to issue any Shares, a special resolution will be proposed at the Annual General Meeting that the Board be granted a general and unconditional mandate to exercise the power of the Company to allot, issue and/or deal with additional Shares and to sell or transfer treasury shares of the Company (if any) not exceeding 20% of the total number of issued Shares of the Company (excluding any treasury shares) as at the date of the relevant resolution to be proposed and passed at the Annual General Meeting, as well as to authorize the Board to make corresponding amendments to the Articles of Association so as to reflect the increase in registered capital and changes to the shareholding structure of the Company upon any allotment and issuance of Shares under the above general mandate.

Further details of the proposed special resolution with respect to the granting of the general mandate to issue Shares are set out in the notice of the Annual General Meeting enclosed.

(9) Proposed Grant of General Mandate to the Board to Repurchase H Shares

In order to provide flexibility to the Company to repurchase H Shares if and when appropriate, a special resolution will be proposed to the AGM to grant to the Board the Repurchase Mandate, details of which are set out in the notice of the AGM.

The H Shares which may be repurchased pursuant to the Repurchase Mandate shall not exceed 10% of the total number of issued H Shares of the Company (excluding treasury shares) as at the date of passing of the resolution(s) approving the Repurchase Mandate.

LETTER FROM THE BOARD

The Repurchase Mandate will be conditional upon the special resolution(s) for approving the grant of the Repurchase Mandate being passed at the AGM. Such Repurchase Mandate, if approved, will lapse at the earliest of: (a) the conclusion of the next annual general meeting of the Company following the passing of the relevant special resolution(s) at the AGM, or (b) the date on which the authority conferred by the relevant special resolution(s) is revoked or varied by a resolution of the Shareholders at any general meeting of the Company.

If the Company repurchases any H Shares pursuant to the Repurchase Mandate, the Company will either (i) cancel the H Shares repurchased and reduce the Company's registered capital in compliance with the applicable laws and regulations; and/or (ii) hold such H Shares in treasury, subject to the situation including market conditions and the Company's capital management needs at the relevant time any repurchases of H Shares are made. If the Company holds any H Shares in treasury, any sale or transfer of H Shares in treasury will be made pursuant to the terms of the general mandate to issue Shares of the Company as set out in the notice of AGM and in accordance with the Listing Rules and applicable laws and regulations of the PRC.

An explanatory statement for the Repurchase Mandate is set out in Appendix I to this circular.

(10) Proposed Change of Registered Address and Amendments to the Articles of Association

Reference is made to the announcement of the Company dated June 1, 2026. The Board proposes certain amendments to the Articles of Association for the following purposes:

- (i) to amend the registered address of the Company to Building A1, Bay Area Future Science and Technology Park, No. 2 Jigutian Road, Baolong Community, Baolong Street, Longgang District, Shenzhen City, Guangdong Province (廣東省深圳市龍崗區寶龍街道寶龍社區積谷田路2號灣區未來科技園A1棟) (subject to the details to be registered with the registration authority);
- (ii) to provide more flexibility to the Company in relation to the conduct of general meetings (including hybrid meetings); and
- (iii) to implement necessary housekeeping amendments to the Articles of Association as a result of the Company's successful listing on the Stock Exchange.

The proposed change of the registered address of the Company and the corresponding proposed amendments to the Articles of Association shall ultimately be subject to the approval of the market supervision and administration authority. Further, the proposed change of the registered address of the Company will be effective upon the Company obtaining all necessary regulatory approvals.

LETTER FROM THE BOARD

Details of the specific proposed amendments to the Articles of Association are set out in Appendix II. The legal advisors of the Company as to Hong Kong laws have confirmed that the proposed amendments conform with the requirements of the Listing Rules and the legal advisors of the Company as to the PRC laws have confirmed that the proposed amendments are not inconsistent with the applicable laws of the PRC.

The proposed change of the registered address of the Company and the proposed amendments to the Articles of Association were considered and approved by the Board on June 1, 2026, and are hereby submitted to the Annual General Meeting for consideration. It is also proposed at the Annual General Meeting to authorize the Board, and the Board further to delegate the authority to the chairman of the Board and the persons authorized by him, to make adjustments to the registered address and the contents of these amendments to the Articles of Association in accordance with the requirements and recommendations of the relevant domestic and overseas regulatory authorities, as well as changes in domestic and overseas laws, regulations and other normative documents.

The Articles of Association are written in both Chinese and English languages. In case of any inconsistency between the Chinese and English versions, the Chinese version shall prevail.

III. THE ANNUAL GENERAL MEETING

The Annual General Meeting will be held at Multi-function Hall, 19/F, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC on Thursday, June 25, 2026 at 10:00 a.m. Notice convening the Annual General Meeting is set out on pages 16 to 21 of this circular and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.edgemed.cn).

IV. CLOSURE OF REGISTER OF MEMBERS

The register of members of the H Shares of the Company will be closed from Monday, June 22, 2026 to Thursday, June 25, 2026, both days inclusive, during which period no transfer of H Shares shall be registered, in order to determine the eligibility of Shareholders who are entitled to attend and vote at the Annual General Meeting to be held on Thursday, June 25, 2026. Shareholders whose names appear on the register of members of the Company on Thursday, June 25, 2026 will be entitled to attend and vote at the Annual General Meeting. The record date for determining the entitlement to attend and vote at the Annual General Meeting is Thursday, June 25, 2026.

In order to be eligible to attend and vote at the Annual General Meeting, all transfer accompanied by relevant share certificates and transfer forms must be lodged with the Company's H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong before 4:30 p.m. on Thursday, June 18, 2026.

V. PROXY ARRANGEMENT

The form of proxy of the Annual General Meeting is enclosed and published on the websites of the Stock Exchange and the Company.

LETTER FROM THE BOARD

If you intend to appoint a proxy to attend the Annual General Meeting, you are required to complete and return the accompanying form of proxy in accordance with the instructions printed thereon. For holders of H Shares, the form of proxy should be returned to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong; for holders of Unlisted Shares, the form of proxy should be returned to the Company's head office and principal place of business in the PRC, at Room 1901, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC, by personal delivery or by post, not less than 24 hours before the time fixed for holding the Annual General Meeting (i.e. not later than 10:00 a.m. on Wednesday, June 24, 2026) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the Annual General Meeting or at any other adjourned meeting should you so wish.

VI. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at the Annual General Meeting must be taken by poll except where the chairman of the Annual General Meeting, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. The Company shall publish the poll results announcement in the manner prescribed under Rule 13.39(5) of the Listing Rules. Accordingly, the chairman of the Annual General Meeting will exercise his power under the Articles of Association to demand a poll in relation to all the proposed resolutions at the Annual General Meeting.

To the best of the Directors' knowledge, information and belief, none of the Shareholders are required to abstain from voting at the Annual General Meeting.

VII. RECOMMENDATION

The Board considers that all the resolutions proposed at the Annual General Meeting are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favor of these proposed resolutions.

VIII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,

By order of the Board

Shenzhen Edge Medical Co., Ltd.

深圳市精鋒醫療科技股份有限公司

Dr. Wang Jianchen

Chairman of the Board and Executive Director

APPENDIX I EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE

In accordance with the Listing Rules, this appendix serves as the explanatory statement to provide you with requisite information reasonably necessary to enable you to make an informed decision on whether to vote for or against the special resolution to be proposed at the AGM for the granting of the Repurchase Mandate to the Board.

SHARE CAPITAL

As at the Latest Practicable Date, the total number of Shares issued by the Company was 391,880,500 (comprising 64,119,252 Unlisted Shares and 327,761,248 H Shares). Subject to the passing of the proposed resolution for the grant of the Repurchase Mandate and on the basis that no H Shares will be allotted and issued or repurchased by the Company on or prior to the date of the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 32,776,124 H Shares, being 10% of the total number of H Shares of the Company (excluding treasury shares) as at the date of passing the relevant resolution(s).

REASONS FOR REPURCHASING SHARES

The Board considered that the repurchase of the H Shares would be beneficial to and in the best interests of the Company and its Shareholders as a whole. It can strengthen the investors' confidence in the Company and promote a positive effect on maintaining the Company's reputation in the capital market. Such repurchases will only be made when the Board believes that such repurchases will benefit the Company and its Shareholders as a whole.

EXERCISE OF THE REPURCHASE MANDATE

Subject to the passing of the special resolution No. 9 as set out in the notice of AGM, the Board will be granted the Repurchase Mandate until the earliest of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of the relevant special resolution(s) at the AGM; or
- (ii) the date on which the authority conferred by the relevant special resolution(s) is revoked or varied by a resolution of the Shareholders at a general meeting.

(hereinafter referred to as the "**Relevant Period**").

The exercise of the Repurchase Mandate is subject to relevant approval of and/or filings with the relevant regulatory authorities as required by the laws, rules and regulations of the PRC being obtained and/or carried out.

FUNDING OF REPURCHASE

In repurchasing its H Shares, the Company intends to apply funds from the Company's internal resources (which may include surplus funds and retained profits) legally available for such purpose in accordance with the Articles of Association and the applicable laws, rules and regulations of the PRC.

The Company is entitled by its Articles of Association to repurchase its H Shares. Any repurchases by the Company may only be made out of either the funds of the Company that would otherwise be available for dividend or distribution or out of the proceeds of a new issue of shares made for such purpose. Under the PRC laws, H Shares so repurchased should be cancelled and the Company's registered capital should be reduced by an amount equivalent to the aggregate nominal value of the H Shares so cancelled, or where appropriate, held in treasury, sold or transferred in compliance with relevant PRC laws and regulations. The Company may not purchase securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

IMPACT ON WORKING CAPITAL

The Directors consider that there would not be any material adverse impact on the working capital or on the gearing position of the Company in the event that the Repurchase Mandate is exercised in full at any time during the proposed repurchase period (as compared with the position disclosed in the latest published audited accounts of the Company for the year ended December 31, 2025). However, the Directors do not propose to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements or the gearing levels of the Company. The number of H Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Board at the relevant time having regard to the circumstances then prevailing, in the best interests of the Company.

EXERCISE OF POWER

The Directors will exercise the powers of the Company to make repurchases under the Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and the applicable laws, rules and regulations of the PRC. The Directors confirm that neither this explanatory statement nor the proposed Repurchase Mandate has any unusual features.

APPENDIX I EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE

H SHARES PRICES

The highest and lowest prices at which the H Shares have been traded on the Stock Exchange from the Listing Date to the Latest Practicable Date were as follows:

	Highest	Lowest
	<i>HK\$</i>	<i>HK\$</i>
2026		
January	70.95	56.00
February	69.70	58.25
March	64.10	51.80
April	58.00	52.00
May (up to the Latest Practicable Date)	59.75	49.82

EFFECT OF THE TAKEOVERS CODE

If as a result of a repurchase of H Shares by the Company pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purpose of Rule 32 of the Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert, depending on the level of increase of the interest in the voting rights of the Company, could obtain or consolidate control of the Company or further become obligated to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, and to the best knowledge and belief of the Directors, Dr. Wang Jianchen and Dr. Gao Yuanqian are interested in 120,068,806 H Shares and 46,868,863 Unlisted Shares, representing approximately 42.60% of the total issued share capital of the Company. Assuming that there is no issue of Shares between the Latest Practicable Date and the date of a repurchase, to the best knowledge and belief of the Directors, if the Repurchase Mandate is exercised in full, the aggregate percentage shareholding of Dr. Wang and Dr. Gao in the Company would increase to approximately 46.49% of the then issued share capital of the Company. Such increase may give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code. The Directors have no present intention to exercise the Repurchase Mandate to such an extent so as to trigger a mandatory offer.

In addition, the Directors do not have any intention to exercise the proposed Repurchase Mandate to the effect that it will result in the public float to fall below the percentage as required under the Listing Rules or such other minimum percentage agreed by the Stock Exchange from time to time.

Save as disclosed above, the Directors are not aware of any consequences which will arise under the Takeovers Code or any similar applicable law.

INTENTIONS TO SELL H SHARES TO THE COMPANY

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their close associates (as defined in the Listing Rules) presently intends to sell H Shares to the Company under the Repurchase Mandate in the event that the Repurchase Mandate is approved by the Shareholders and the conditions (if any) to the Repurchase Mandate are fulfilled.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any H Shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company in the event that the Repurchase Mandate is approved by its Shareholders and the conditions (if any) to which the Repurchase Mandate are fulfilled.

The Company had not repurchased any of the Shares (whether on the Stock Exchange or otherwise) from the Listing Date to the Latest Practicable Date.

If the Company repurchases any H Shares pursuant to the Repurchase Mandate, the Company will either (i) cancel the H Shares repurchased and reduce the Company's registered capital in compliance with the applicable laws and regulations; and/or (ii) hold such H Shares in treasury, subject to the situation including market conditions and the Company's capital management needs at the relevant time when any repurchases of H Shares are made.

Before amendment	After amendment
<p>Article 3 The Company completed its filing with the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on [●], and obtained the approval of The Stock Exchange of Hong Kong Limited (hereinafter referred to as “Hong Kong Stock Exchange”) on [●] for its initial offering of [●] ordinary shares in the form of overseas listed shares (hereinafter referred to as “H Shares”) to overseas investors, with a par value of RMB1.00 per share, and were listed on the Main Board of Hong Kong Stock Exchange on [●].</p>	<p>Article 3 The Company completed its filing with the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on <u>December 11, 2025</u>, and obtained the approval of The Stock Exchange of Hong Kong Limited (hereinafter referred to as “Hong Kong Stock Exchange”) on <u>January 7, 2026</u> for its initial offering of <u>27,722,200</u> ordinary shares in the form of overseas listed shares (hereinafter referred to as “H Shares”) to overseas investors (<u>prior to the full exercise of the over-allotment option</u>), with a par value of RMB1.00 per share, and were listed on the Main Board of Hong Kong Stock Exchange on <u>January 8, 2026</u>.</p>
<p>Article 5 Address of the Company: 2B1901, Phase II, Smart Park, No. 76 Baohe Avenue, Baolong Community, Baolong Street, Longgang District, Shenzhen, Postal Code: 518100.</p>	<p>Article 5 Address of the Company: 2B1901, Phase II, Smart Park, No. 76 Baohe Avenue, Baolong Community, Baolong Street, Longgang District, Shenzhen <u>Building A1, Bay Area Future Science and Technology Park, No. 2 Jigutian Road, Baolong Community, Baolong Street, Longgang District, Shenzhen City, Guangdong Province</u> (subject to the registration with the competent registration authority), Postal Code: <u>518116518100</u>.</p>
<p>Article 6 The registered capital of the Company is RMB[●] million.</p>	<p>Article 6 The registered capital of the Company is RMB<u>360</u> million.</p>
<p>Article 21 After the completion of the initial public offering of H shares, assuming that the over-allotment option is not exercised, the share capital structure of the Company shall be: [●] ordinary shares, comprising [●] domestic unlisted shares and [●] overseas listed shares; assuming that all over-allotment options are exercised, the share capital structure of the Company shall be: [●] ordinary shares, comprising [●] domestic unlisted shares and [●] overseas listed shares. The total number of shares of the Company upon completion of the offering and listing of H Shares shall be [●] shares, all of which are ordinary shares.</p>	<p>Article 21 After the completion of the initial public offering of H shares, assuming that the over-allotment option is not exercised, the share capital structure of the Company shall be: [●] ordinary shares, comprising [●] domestic unlisted shares and [●] overseas listed shares; assuming that all over-allotment options are exercised, the <u>The</u> share capital structure of the Company shall be: <u>391,880,500</u> ordinary shares, comprising <u>64,119,252</u> domestic unlisted shares and <u>327,761,248</u> overseas listed shares. The total number of shares of the Company upon completion of the offering and listing of H Shares shall be [●] shares, all of which are ordinary shares.</p>

Before amendment	After amendment
<p>Article 47 A venue shall be set up for the General Meeting, and the meeting shall be convened in the form of an on-site meeting. The Company shall also, in accordance with the provisions of laws, regulations or the Articles of Association, provide online, video, telephone or other means to facilitate shareholders' participation in the General Meeting. Shareholders who participate in the General Meeting through the aforesaid means shall be deemed to have attended the meeting.</p>	<p>Article 47 A venue shall be set up for the General Meeting, and the meeting<u>which shall be convened in the</u>physical, electronic form of an on-site meeting. <u>(such as video conference and/or telephone conference), hybrid or other forms permitted by laws and regulations.</u> The Company shall<u>may</u> also, in accordance with the provisions of laws, regulations<u>of laws, regulations</u> or the Articles of Association, provide online, video, telephone or other<u>or other</u> means to facilitate shareholders' participation in the General Meeting. Shareholders who participate in the General Meeting through the aforesaid means shall be deemed to have attended the meeting.</p>
<p>Article 222 The Articles of Association are passed by a special resolution of the General Meeting of the Company and shall take effect and be implemented as of the date on which the H shares publicly offered by the Company are listed for trading at the Main Board of the Hong Kong Stock Exchange. The original Articles of Association of the Company shall be automatically invalidated as of the date when the Articles of Association take effect.</p>	<p>Article 222 The Articles of Association are passed by a special resolution of the General Meeting of the Company and shall take effect and be implemented as of the date on which the H shares publicly offered by the Company are listed for trading at the Main Board of the Hong Kong Stock Exchange <u>from the date of its approval by a special resolution of the General Meeting of the Company.</u> The original Articles of Association of the Company shall be automatically invalidated as of the date when the Articles of Association take effect.</p>

NOTICE OF ANNUAL GENERAL MEETING



Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2675)

NOTICE OF THE ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the “**Annual General Meeting**”) of Shenzhen Edge Medical Co., Ltd. (the “**Company**”) will be held at Multi-function Hall, 19/F, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC on Thursday, June 25, 2026 at 10:00 a.m. for the following purposes:

ORDINARY RESOLUTIONS

1. To consider and approve the report of the board of directors of the Company (the “**Board**”) for the year 2025;
2. To consider and approve the report of the supervisory committee of the Company for the year 2025;
3. To consider and approve the annual report of the Company for the year 2025;
4. To consider and approve the profit distribution plan of the Company for the year 2025;
5. To consider and approve the re-appointment of auditor of the Company for the year 2026;
6. To consider and approve the proposed authorization to the Board to fix the remuneration of directors and supervisors of the Company; and
7. To consider and approve the proposed change of company type of the Company.

SPECIAL RESOLUTIONS

8. To consider and approve granting of a general mandate to the Board to exercise the right to allot, issue and/or deal with new shares of the Company:

“THAT:

- (a) subject to the limitations imposed by (c) and (d) below and in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”), the Company Law of

NOTICE OF ANNUAL GENERAL MEETING

the People's Republic of China ("PRC"), and other applicable laws and regulations (in each case as amended from time to time), a waiver of the relevant restrictions and requirements (if any) in the articles of association of the Company (the "Articles of Association") is granted hereby and a general and unconditional mandate be and is hereby granted to the Board to exercise once or more during the "Relevant Period" (as defined below) all the powers of the Company to allot, issue and/or deal with new shares and to sell or transfer treasury shares of the Company (if any) on such terms and conditions the Board may determine and that, in the exercise of their powers to allot, issue and/or deal with shares and to sell or transfer treasury shares of the Company (if any), the authority of the Board shall include (without limitation):

- (i) the determination of the class and number of the shares to be allotted and issued;
 - (ii) the determination of the issue price of the new shares;
 - (iii) the determination of the opening and closing dates of the issue of new shares;
 - (iv) the determination of the class and number of new shares (if any) to be issued to the existing shareholders;
 - (v) to determine the use of proceeds;
 - (vi) to make or grant offers, agreements and options which might require the issue, allotment or disposal of such new shares; and
 - (vii) in the case of an offer or issue of shares to the shareholders of the Company, excluding shareholders who are residents outside the PRC or the Hong Kong Special Administrative Region, on account of prohibitions or requirements under overseas laws or regulations or for some other reasons which the Board consider expedient;
- (b) upon the exercise of the powers granted under paragraph (a), the Board may during the "Relevant Period" make or grant offers, agreements and options which might require the shares relating to the exercise of the authority thereunder being allotted and issued after the expiry of the "Relevant Period";
- (c) the aggregate number of H Shares and Unlisted Shares authorized to be issued by the Board pursuant to the authority granted under paragraph (a) above (excluding any shares which may be allotted upon the conversion of the capital reserve (資本公積) into capital in accordance with the

NOTICE OF ANNUAL GENERAL MEETING

Company Law of the PRC or the Articles of Association) shall not exceed 20% of the total number of the issued Shares of the Company (excluding any treasury shares) as at the date of this resolution being approved at the AGM;

- (d) the Board in exercising the powers granted under paragraph (a) above shall (i) comply with the Company Law of the PRC, other applicable laws and regulations of the PRC, and the Listing Rules (in each case, as amended from time to time) and (ii) be subject to the approvals of the China Securities Regulatory Commission and relevant authorities of the PRC (if any);
- (e) the Board shall, subject to the relevant approvals of the relevant authorities and the exercise of the power granted under paragraph (a) above in accordance with the Company Law and other applicable laws and regulations of the PRC, increase the Company's registered capital based on the waiver granted under paragraph (a) above corresponding to the relevant number of shares allotted upon the exercise of the powers granted under paragraph (a) of this resolution, provided that the registered capital of the Company shall not exceed 120% of the amount of registered capital of the Company as at the date of passing of this resolution;
- (f) the Board be and they are hereby authorized based on the waiver granted under paragraph (a) above to amend, as they may deem appropriate and necessary, relevant articles of the Articles of Association of the Company to reflect the change in the share capital structure of the Company in the event of an exercise of the powers granted under paragraph (a) to allot and issue new shares.

For the purposes of this resolution: "Relevant Period" means the period from the date of the passing of this resolution until whichever is the earlier of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of this resolution; or
- (ii) the date on which the powers granted by this resolution are revoked or varied by a resolution of the Company in general meeting."

NOTICE OF ANNUAL GENERAL MEETING

9. To consider and approve the proposed grant of general mandate to the Board to repurchase H Shares.
- (a) subject to resolution number 9(b) below, waiving the relevant restrictions and requirements (if any) in the Articles of Association and granting to the Board a general mandate during the Repurchase Mandate Period (as defined below) to, in accordance with all applicable laws and regulations of the PRC government or securities regulators, the Hong Kong Stock Exchange, the Hong Kong Securities and Futures Commission or any other government or regulatory agency, in order to safeguard the Company's value and Shareholders' interests, and on such terms as they deem fit, exercise all the power of the Company to repurchase part of the issued H Shares on the Hong Kong Stock Exchange and handle related matters, including but not limited to the specific plan for the repurchase of relevant H Shares (including but not limited to repurchase price, number of H Shares to be repurchased, time of repurchase, etc.) as formulated, adjusted or terminated by the Board in accordance with relevant laws and regulations, and full authority to handle repurchase, cancellation of relevant H Shares or hold the repurchased H Shares as treasury shares to the extent permitted under the Listing Rules and applicable laws and regulations. The Board is entitled to authorize its authorized persons to handle relevant matters in full according to the specific plan for the repurchase of relevant H Shares reviewed and approved by the Board;
 - (b) the total number of H Shares which may be repurchased by the Company within the Repurchase Mandate Period pursuant to the approval in resolution number 9(a) above shall not exceed 10% of the total number of H Shares of the Company (excluding treasury shares) on the date of passing of this resolution;
 - (c) based on the Company's actual operation and stock price performance, the Board has the power to decide on the implementation or termination of specific plans in relation to the repurchase of H Shares (if any);
 - (d) based on the actual situation of repurchase of H Shares and the waiver granted under paragraph (a) above, cancel the repurchased H Shares, reduce registered capital of the Company, make corresponding amendments to the Articles of Association, notify the creditors of the Company, publish announcements and convene bondholders' meetings (if applicable) in accordance with relevant laws and regulations and the Articles of Association, and carry out relevant statutory registrations and filings, and/or hold the repurchased H Shares as treasury shares to the extent permitted under the Listing Rules and applicable laws and regulations; and
 - (e) other matters related to the repurchase of H Shares, except those which are expressly stipulated by relevant laws and regulations to be exercised by the Shareholders at a general meeting and which are not authorized to the Board.

NOTICE OF ANNUAL GENERAL MEETING

For the purpose of this resolution, “Repurchase Mandate Period” refers to the period commencing from the date on which this resolution is considered and approved at the general meeting to the earlier of: (1) the conclusion of the next annual general meeting of the Company; or (2) the date on which the mandate granted under this resolution is revoked or varied by resolution at any general meeting of the Company.

10. To consider and approve the proposed change of registered address and amendments to the Articles of Association:

“THAT

the proposed change of the registered address and amendments to the Articles of Association of the Company be and are hereby approved and the Board and/or its authorized person(s) be and is hereby authorized to deal with on behalf of the Company all relevant procedures and matters to effect the change and amendments and to make any appropriate adjustments thereto whenever necessary in the process of submitting the same for the approval of and as required from time to time by the relevant regulatory authorities.”

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. All resolutions at the Annual General Meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the websites of the Company at www.edgemed.cn and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk after the Annual General Meeting.
2. Any shareholder entitled to attend and vote at the Annual General Meeting convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company's H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H shares), or the Company's head office and principal place of business in the PRC, at Room 1901, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC (for holders of Unlisted Shares), at least 24 hours before the Annual General Meeting (i.e. before 10:00 a.m. on Wednesday, June 24, 2026) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting at the Annual General Meeting or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the list of shareholders who are entitled to attend the Annual General Meeting, the H share register of members of the Company will be closed from Monday, June 22, 2026 to Thursday, June 25, 2026, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of the shares shall ensure that all properly completed transfer documents accompanied by the relevant share certificates are lodged with the Company's H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Thursday, June 18, 2026 for registration. The record date for determining the entitlement to attend and vote at the Annual General Meeting is Thursday, June 25, 2026.
5. In case of joint shareholders, the vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
7. A shareholder or his/her proxy should produce proof of identity when attending the Annual General Meeting.
8. References to date and time in this notice are to Hong Kong dates and time.

By order of the Board
Shenzhen Edge Medical Co., Ltd.
(深圳市精鋒醫療科技股份有限公司)

Dr. Wang Jianchen
Chairman of the Board and Executive Director

Hong Kong, June 3, 2026

As at the date of this notice, the Board comprises Dr. Wang Jianchen, Dr. Gao Yuanqian, and Ms. Wu Mengyuan as executive directors; Mr. Sheng Li, Mr. Chen Gang, and Mr. Qiu Xiang as non-executive directors; and Mr. Yang Fan, Mr. Zhang Guoguang and Mr. Lau Ying Kit as independent non-executive directors.